Company Filing History:

14 out of 1,008

Bayer Corporation

patents

2 out of 70

Bayer Pharmaceuticals Corporation

patents

1 out of 832,680

Other

patents

Years Active: 1998-2005

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6911449 - Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids (2005-06-28),

2. 6762184 - Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids (2004-07-13),

3. 6541468 - Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer (2003-04-01),

4. 6500847 - Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acids (2002-12-31),

5. 6225314 - Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids (2001-05-01),

6. 6166082 - Substituted 5-biarylpentanoic acids and derivatives as matrix (2000-12-26),

7. 6013646 - Indolocarbazole derivatives useful for the treatment of (2000-01-11),

8. 5932577 - Substituted oxobutyric acids as matrix metalloprotease inhibitors (1999-08-03),

9. 5925637 - Inhibition of matrix metalloproteases by substituted biaryl oxobutyric (1999-07-20),

10. 5886043 - Substituted 4-biarylbutyric acid derivatives as matrix metalloprotease (1999-03-23),

11. 5886022 - Substituted cycloalkanecarboxylic acid derivatives as matrix (1999-03-23),

12. 5874473 - Substituted cycloalkanecarboxylic acid derivatives as matrix (1999-02-23),

13. 5861428 - Substituted 4-biarylbutyric acid derivatives as matrix metalloprotease (1999-01-19),

14. 5861427 - Substituted 4-biarylbutyric acid derivatives as matrix metalloprotease (1999-01-19),

15. 5859047 - Substituted 4-biarylbutyric acid derivatives as matrix metalloprotease (1999-01-12),

Title: Michael C VanZandt: Innovator in Matrix Metalloprotease Inhibition

Introduction

Michael C VanZandt is a notable inventor based in Guilford, CT (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the area of matrix metalloprotease inhibition. With a total of 17 patents to his name, VanZandt's work has the potential to impact various medical conditions.

Latest Patents

One of his latest patents focuses on the inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids. This invention presents matrix metalloprotease inhibiting compounds, pharmaceutical compositions, and methods for treating diseases associated with these enzymes. The compounds are designed to combat conditions such as osteoarthritis, rheumatoid arthritis, and tumor metastasis, among others. The generalized formulas of these compounds include specific structural components that enhance their efficacy in inhibiting matrix metalloproteases.

Career Highlights

Throughout his career, Michael C VanZandt has worked with prominent organizations, including Bayer Corporation and Bayer Pharmaceuticals Corporation. His experience in these companies has allowed him to develop innovative solutions that address critical health issues.

Collaborations

Some of his notable coworkers include Brian R Dixon and David R Brittelli. Their collaborative efforts have contributed to the advancement of research in the field of matrix metalloprotease inhibition.

Conclusion

Michael C VanZandt's contributions to the field of pharmaceutical sciences through his innovative patents demonstrate his commitment to improving health outcomes. His work continues to pave the way for new treatments for various medical conditions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.